UNSPSC 51433606: Minoxidil sulfate ester

This classification denotes a vasodilating agent and antihypertensive agent with the molecular formula C9H15N5O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H6K6Y231J, chemically known as 2-pyrimidinamine, 1,6-dihydro-6-imino-4-(1-piperidinyl)-1-(sulfooxy)-, but more generally known as minoxidil sulfate ester, which bears US NIH Compound Identifier 4202. European Medicines Agency schedules minoxidil sulfate ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08982MIG.

Most nations, for tariff purposes, schedule minoxidil sulfate ester under HS 29335995. SMILES: C1C([N+](C(NC1N2CCCCC2)N)OS(=O)(=O)[O-])N.

UNSPSC 51433606 Minoxidil sulfate ester is a Commodity code that in recent state and local procurement activity covers emergency medical and health system pharmaceuticals — not the dermatological product the code name suggests, but rather advanced life support medications, generic multi-source pharmaceuticals, and prescription fulfillment programs sourced through state health agencies and municipal emergency services. State and local governments buying under this code include city fire-rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances administering pharmaceutical supply to hospital systems, health plans, and emergency response units. The work ranges from sealed-bid procurement of specific emergency medications (epinephrine, labetalol, adenosine, diltiazem) with strict expiration and delivery requirements, to RFP-based framework agreements for generic pharmaceutical catalogs distributed through authorized wholesaler networks, to exploratory requests for information on direct-to-manufacturer prescription programs that bypass traditional pharmacy benefit managers.

Recent activity appears concentrated in Florida and Texas, with broader multistate reach through cooperative purchasing vehicles. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications on April 24, 2026, with response due April 8, 2026, requiring sealed bids for four medication line items totaling an estimated $40,000 contract value and including a 5 percent Small Local Business Enterprise bid discount. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) on January 20, 2026, with response due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities including Oregon, with pricing weighted at 75 percent and awards effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling future formal procurement interest in alternative pharmacy distribution models.